SCD-101 / Invenux - LARVOL DELTA

Anti-sickling efficacy and safety of Sailin-HbS, an indigenous Ayurvedic formulation. (PubMed, Blood Cells Mol Dis) - "We compared the anti-sickling effect of Sailin-HbS with known anti-sickling agents, Niprisan, SCD 101, AES-103/5-HMF and GBT440/Voxelotor, and found it to be equally and/or more effective. Sub-acute and chronic toxicity assessments in rats reveal no adverse effects on organ function or body weight, biochemical parameters, or complete blood counts, demonstrating its safety profile with established threshold levels. Thus, Sailin-HbS exhibits considerable anti-sickling efficacy without inducing toxicity, suggesting its translational potential in SCD."

Journal • Gene Therapies • Genetic Disorders • Hematological Disorders • Pain • Sickle Cell Disease

Dose-Escalation Study of SCD-101 in Sickle Cell Disease (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Invenux, LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2021 ➔ Dec 2023 | Trial primary completion date: Aug 2021 ➔ Nov 2023

Enrollment closed • Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

SCD 101: Perspectives on Diagnosis to Treatment (ASH 2022) - "This program is supported by Global Blood Therapeutics, Inc."

Dose-Escalation Study of SCD-101 in Sickle Cell Disease (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Invenux, LLC; Trial completion date: Dec 2020 ➔ Nov 2021; Trial primary completion date: Oct 2020 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Dose-Escalation Study of SCD-101 in Sickle Cell Disease (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Invenux, LLC; Trial completion date: Dec 2018 ➔ Dec 2020; Trial primary completion date: Oct 2018 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date